Trials / Unknown
UnknownNCT00360763
Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 600 (planned)
- Sponsor
- Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in patients with hypertension. ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertension. The present study is to explore whether AT1 receptor blocker has superior anti-hypertensive effect in patients with positive ATR-AA hypertension. Patients with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA. A study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE inhibitor imidapril.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | candesartan cilexetil |
Timeline
- Completion
- 2006-12-01
- First posted
- 2006-08-07
- Last updated
- 2006-08-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00360763. Inclusion in this directory is not an endorsement.